Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Effective treatments for advanced/recurrent head and neck squamous-cell carcinoma are limited. For cases not curable by conventional local therapies, the immune checkpoint inhibitor pembrolizumab shows modest response rates. Quad-shot, a hypofractionated palliative radiotherapy regimen (14.8 Gy in f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Ryan T, Gebeyehu, Rediet R, Kalada, John Mason, Lycan, Thomas W, Frizzell, Bart A, Kinney, Rebecca D, D'Agostino, Ralph B, Bunch, Paul M, Triozzi, Pierre, Zhang, Wei, Furdui, Cristina M, Porosnicu, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463211/
https://www.ncbi.nlm.nih.gov/pubmed/37199326
http://dx.doi.org/10.2217/fon-2022-1146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463211/
https://www.ncbi.nlm.nih.gov/pubmed/37199326
http://dx.doi.org/10.2217/fon-2022-1146

Ejemplares similares